Decreasing soluble CD30 and increasing IFN-γ plasma levels are indicators of effective highly active antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 23, Issue 7, 2007, Pages 886-890

  Sadeghi, Mahmoud ^a   Süsal, Caner ^a   Daniel, Volker ^a   Naujokat, Cord ^a   Zimmermann, Rainer ^b   Huth Kühne, Angela ^b   Opelz, Gerhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Kurpfalz Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD30 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 7; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; HEMOPHILIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VIRUS LOAD; BLOOD; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD30; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HIV INFECTIONS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-6; MALE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34547927629     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0228     Document Type: Article

References (23)

1. Norris PJ and Rosenberg ES: Cellular immune response to human immunodeficiency virus. AIDS 2001;15(Suppl. 2):S16-21.
2. Clerici M, Galli M, Bosis S, Gervasoni C, Moroni M, and Nor3 biato G: Immunoendocrinologic abnormalities in human immunodeficiency virus infection. Ann NY Acad Sci 2000;917:956-961.
3. Valdez H and Lederman MM: Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997-98:187-228.
4. Verheggen R: Immune restoration in patients with HIV infection: HAART and beyond. J Assoc Nurses AIDS Care 2003;14:76-82.
5. Stone SF, Price P, and French MA: Immune restoration disease: A consequence of dysregulated immune responses after HAART. Curr HIV Res 2004;2:235-242.
6. Resino S, Rivero L, Ruiz-Mateos E, et al.: Immunity in HIV-1-infected adults with a previous state of moderate-severe immune-suppression and more than 500 CD4+ T cell after highly active antiretroviral therapy. J Clin Immunol 2004;24:379-388.
7. Giovannetti A, Pierdominici M, Mazzetta F, et al.: T cell responses to highly active antiretroviral therapy defined by chemokine receptors expression, cytokine production, T cell receptor repertoire and anti-HIV T-lymphocyte activity. Clin Exp Immunol 2001; 124:21-31.
8. Fournier S, Rabian C, Alberti C, et al.: Recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens. J Infect Dis 2001;183: 1586-1591.
9. Brazille P, Dereuddre-Bosquet N, Leport C, et al.: Decreases in plasma TNF-alpha level and IFN-gamma mRNA level in peripheral blood mononuclear cells (PBMC) and an increase in IL-2 mRNA level in PBMC are associated with effective highly active antiretroviral therapy in HIV-infected patients. Clin Exp Immunol 2003;131:304-311.
10. Mastroianni CM, Forcina G, d'Ettorre G, et al.: Circulating levels of interleukin-7 in antiretroviral-naive and highly active antiretroviral therapy-treated HIV-infected patients. HIV Clin Trials 2001; 2:108-112.
11. Darcissac EC, Vidal V, De La Tribonniere X, Mouton Y, and Bahr GM: Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical change following antiretroviral therapy. Clin Exp Immunol 2001;126:287-294.
12. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, and Pizzolo G: CD30 and type 2 T helper (Th2) responses. Leukoc Biol 1995;57:726-730.
13. Pizzolo G, Vinante F, Nadali G, et al.: High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 1997;108:251-253.
14. Keane NM, Price P, Lee S, Stone SF, and French MA: An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 2001;126:111-116.
15. French M and Price P: Immune restoration disease in HIV patients: Aberrant immune responses after antiretroviral therapy. J HIV Ther 2002;7:46-51.
16. Rizzardi GP, Barcellini W, Tambussi G, et al.: Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: Correlation with HIV-1 RNA and the clinical outcome. AIDS 1996;10:F45-50.
17. Daniel V, Süsal C, Melk A, et al.: Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients. Immunol Lett 1999;69:283-289.
18. Imami N, Antonopoulos C, Hardy GA, Gazzard B, and Gotch FM: Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: Impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 1999;15:1499-1508.
19. Mylonakis E, Paliou M, and Rich JD: Plasma viral load testing in the management of HIV infection. Am Fam Physician 2001;63: 483-490, 495-496.
20. Costello C, Nelson KE, Suriyanon V, et al.: HIV-1 subtype E progression among northern Thai couples: Traditional and non-traditional predictors of survival. Int J Epidemiol 2005;34:577-584.
21. Lieberman J, Shankar P, Manjunath N, and Andersson J: Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001;98:1667-1677.
22. Benito JM, Lopez M, Lozano S, et al.: Phenotype and functional characteristics of HIV-specific cytotoxic CD8+ T cells in chronically infected patients: Dual effects of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003;34:255-266.
23. Ruiz-Mateos E, de la Rosa R, Franco JM, et al.: Endogenous IL-7 is associated with increased thymic volume in adult HIV-infected patients under highly active antiretroviral therapy. AIDS 2003;17: 947-954.